INT272273

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.54
First Reported 2006
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 89
Total Number 123
Disease Relevance 121.19
Pain Relevance 4.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
eyes 12
superior 3
outflow 2
14.1 2
plasma 1
NARFL (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 141 99.90 Very High Very High Very High
ischemia 94 99.64 Very High Very High Very High
agonist 239 99.58 Very High Very High Very High
Serotonin 106 99.40 Very High Very High Very High
sSRI 66 99.36 Very High Very High Very High
corticosteroid 37 98.36 Very High Very High Very High
Inflammation 376 98.24 Very High Very High Very High
fibrosis 17 96.44 Very High Very High Very High
beta blocker 500 93.40 High High
Onset of action 7 92.80 High High
Disease Link Frequency Relevance Heat
Ocular Hypertension 13945 100.00 Very High Very High Very High
Glaucoma 3546 99.84 Very High Very High Very High
Cv Unclassified Under Development 106 99.64 Very High Very High Very High
Low Tension Glaucoma 178 99.48 Very High Very High Very High
Aging 19 99.48 Very High Very High Very High
Disease 275 99.24 Very High Very High Very High
Hypertension 68 99.04 Very High Very High Very High
Uveitis 348 98.84 Very High Very High Very High
Hypotension 800 98.52 Very High Very High Very High
Pressure And Volume Under Development 253 98.30 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Subsequent surgical treatment was needed in 7 of the 40 (4.7%) to reduce high IOP levels that were refractory to maximal medical therapy with 2 or 3 antiglaucomatous drugs.
Gene_expression (levels) of IOP associated with ocular hypertension
1) Confidence 0.54 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698684 Disease Relevance 1.40 Pain Relevance 0
However, in a small percentage of eyes the hypertension may be uncontrollable with topical treatment; in such cases, surgical procedures to reduce the IOP should be carried out (Jonas 2005; Jonas et al 2005).
Gene_expression (reduce) of IOP in eyes associated with pressure and volume under development and ocular hypertension
2) Confidence 0.54 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698684 Disease Relevance 1.05 Pain Relevance 0.04
Surprisingly, the IOP levels during the first week after the injection were statistically significantly higher than the preinjection IOP, but only 2.7% of the eyes showed important IOP elevations.
Gene_expression (higher) of IOP in eyes associated with ocular hypertension
3) Confidence 0.54 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698684 Disease Relevance 1.01 Pain Relevance 0.03
In our series, the rates of topical treatment and surgery for reducing high IOP were 27% and 4.7%, respectively.
Gene_expression (reducing) of IOP associated with ocular hypertension
4) Confidence 0.54 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698684 Disease Relevance 1.14 Pain Relevance 0
Moderate and important IOP elevations above the preoperative baseline were defined as ?
Gene_expression (elevations) of IOP associated with ocular hypertension
5) Confidence 0.54 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698684 Disease Relevance 0.83 Pain Relevance 0.06
Severe and intractable IOP elevations, despite maximally tolerated medical therapy after IVTA, were reported to occur in some eyes, especially those with retinal vein occlusions (Kaushik et al 2004; Yang et al 2005; Quiram et al 2006).
Gene_expression (elevations) of IOP in retinal vein associated with ocular hypertension and retinal vein occlusion
6) Confidence 0.54 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698684 Disease Relevance 1.18 Pain Relevance 0
Rare causes of IOP elevation related to IVTA injection have included an early and rapid rise in IOP related to mechanical obstruction of the trabeculum by triamcinolone particles in pseudophakic eyes, and cases of angle closure and malignant glaucoma (Jonas et al 2003; Singh et al 2004; Sivaprasad et al 2006).
Gene_expression (elevation) of IOP in eyes associated with malignant neoplastic disease, glaucoma and ocular hypertension
7) Confidence 0.54 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698684 Disease Relevance 1.27 Pain Relevance 0.08
Surprisingly, the IOP levels during the first week after the injection were statistically significantly higher than the preinjection IOP, but only 2.7% of the eyes showed important IOP elevations.
Gene_expression (levels) of IOP in eyes associated with ocular hypertension
8) Confidence 0.54 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698684 Disease Relevance 1.00 Pain Relevance 0.03
The persistence of IOP elevation despite cessation of steroid treatment has been known for a long time (Spaeth et al 1977).
Gene_expression (elevation) of IOP associated with ocular hypertension
9) Confidence 0.54 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698684 Disease Relevance 1.23 Pain Relevance 0
Dorzolamide/timolol fixed combination (DTFC) was found to be as effective as the concomitant administration of its components in reducing IOP and has also simplified the therapy for patients needing these two medications (Boyle et al 1991).
Gene_expression (reducing) of IOP associated with ocular hypertension
10) Confidence 0.53 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698680 Disease Relevance 1.43 Pain Relevance 0.06
Eyes that receive IVTA need to be monitored for IOP changes especially during the first 3 months.
Gene_expression (changes) of IOP in Eyes associated with ocular hypertension
11) Confidence 0.42 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2693970 Disease Relevance 0.97 Pain Relevance 0
In conclusion, our data shows that IOP elevation can occur in a significant number of eyes receiving 4 mg of IVTA.
Gene_expression (elevation) of IOP in eyes associated with ocular hypertension
12) Confidence 0.42 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2693970 Disease Relevance 1.09 Pain Relevance 0
Several variables were studied as risk factors for IOP rise.
Gene_expression (rise) of IOP associated with ocular hypertension
13) Confidence 0.42 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2693970 Disease Relevance 1.36 Pain Relevance 0.03
Most of the oxybuprocaine subjects presented with an IOP change within ±2 mmHg (of the initial IOP) after instillation of the eyedrops, with approximately 87% (two minutes and five minutes post eyedrop instillation) showing an IOP change that ranged from +1 mmHg to ?
Gene_expression (change) of IOP associated with ocular hypertension
14) Confidence 0.37 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701119 Disease Relevance 1.16 Pain Relevance 0
1 mmHg and +3 mmHg, there was a significant number of subjects in the anesthetics’ groups that had IOP reductions of 2 mmHg or 3 mmHg (approximately 30% after 2 minutes in both the oxybuprocaine and proparacaine groups and approximately 35% after five minutes in both groups).
Gene_expression (reductions) of IOP associated with ocular hypertension
15) Confidence 0.37 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701119 Disease Relevance 0.76 Pain Relevance 0.05
The results from the current study can not be explained by a transient increase in corneal thickness as such an increase should lead to an overestimation of IOP not an underestimation.
Gene_expression (overestimation) of IOP associated with ocular hypertension
16) Confidence 0.37 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701119 Disease Relevance 0.77 Pain Relevance 0
Although most subjects in all three groups had IOP changes between ?
Gene_expression (changes) of IOP associated with ocular hypertension
17) Confidence 0.37 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701119 Disease Relevance 0.72 Pain Relevance 0.06
The findings of this study agree with those of Baudouin and Gastaud (1994) in which there were average reductions in IOP of 0.76 mmHg (0.7 mmHg, after two minutes, in this study) after one minute and 1.19 mmHg (0.9 mmHg, after five minutes, in this study) after five minutes, with oxybuprocaine.
Gene_expression (reductions) of IOP associated with ocular hypertension
18) Confidence 0.37 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701119 Disease Relevance 0.73 Pain Relevance 0
We found no significant difference between the IOP decrease after two minutes and that after 5 minutes in agreement with Baudouin and Gastaud (1994) who found no significant difference in the IOP reduction at up to 15 minutes with oxybuprocaine.
Neg (no) Gene_expression (reduction) of IOP associated with ocular hypertension
19) Confidence 0.37 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701119 Disease Relevance 0.84 Pain Relevance 0
Most of the oxybuprocaine subjects presented with an IOP change within ±2 mmHg (of the initial IOP) after instillation of the eyedrops, with approximately 87% (two minutes and five minutes post eyedrop instillation) showing an IOP change that ranged from +1 mmHg to ?
Gene_expression (change) of IOP associated with ocular hypertension
20) Confidence 0.37 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701119 Disease Relevance 1.15 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox